Next Phase Newsletter

The firm is the corporate venture capital arm of a diversified industrial group and invests globally from Seed through Series A. The firm typically deploys between USD $250K and $4M per investment. The firm focuses on equity investments and strategic partnerships that complement the parent organization’s healthcare and consumer health activities. The firm invests on a geographically agnostic basis and has recently increased its focus on opportunities in the United States. 

Approximately half of the firm’s investments are allocated to healthcare, centered on three primary pillars: medical devices, therapeutic technologies, and digital health. The firm invests in technology-driven solutions aligned with the broader healthcare ecosystem, including innovations in wound care, diagnostics, telehealth, and other patient-facing or clinical-efficiency solutions. The firm also leverages an in-house teleconsultation platform to support digital health innovation and partnership development. 

From a company and management team perspective, the firm invests in early-stage businesses with strong technological differentiation, clear clinical or operational value propositions, and the ability to scale globally. The firm seeks founders with demonstrated domain expertise and the capacity to execute product development and commercialization strategies within regulated environments. The firm participates flexibly across rounds, acting as a lead, co-lead, or co-investor, and engages with teams that can benefit from the parent organization’s healthcare infrastructure, commercial networks, and international expansion capabilities. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: business, finance, health, investing, technology

The firm is a private investment vehicle established in 2023 and is headquartered in Asia. The firm is focused on global healthcare opportunities. The firm co-invests in Pre-Seed through Series A rounds and currently maintains a small but diversified portfolio across biotech, digital health, and medical devices. Initial check sizes are flexible, with the firm typically allocating up to approximately USD $400K in Seed rounds and USD $1–2M in Series A financings. 

The firm is open to investing across biotech, first-in-class therapeutics, medical devices, digital health, and diagnostics. The firm is indication- and technology-agnostic but prioritizes next-generation and highly innovative technologies with strong differentiation. 

The firm does not impose strict requirements on companies or management teams. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: business, finance, health, investing, technology

A venture capital firm is focused exclusively on digital technologies for advanced bioprocessing. The firm targets growth-stage, revenue-generating companies, typically at the Series A stage. The firm evaluates opportunities in North America and Europe. The firm generally leads investment rounds and often takes board seats. With deep expertise in life science tools, the firm actively supports portfolio companies beyond capital.  

The firm concentrates on life science tools supporting drug development, laboratory automation, bioprocessing, and advanced therapy manufacturing that incorporate meaningful digital components. The firm is highly specialized in this niche and only considers opportunities that align directly with this mandate. The firm invests in companies that are already generating revenue.  

The firm does not impose specific requirements on company structure or management team composition. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: business, finance, health, investing, technology

A venture capital firm is focused on early-stage ventures and has raised multiple funds since inception. The firm primarily makes equity investments, with total capital deployed per company typically ranging from $250K to $5M over the life of the investment and initial checks generally between $100K and $500K. The firm prefers to invest in companies located on the U.S. West Coast but remains open to opportunities across North America. The firm maintains long-standing relationships with several Japanese medical technology corporations and seeks opportunities that may be introduced into the Japanese market. 

The firm targets Seed and early-stage medical device companies, with particular interest in single-use therapeutic devices. The firm prefers opportunities with a 510(k) regulatory pathway but will also consider PMA applications. Areas of strongest interest include interventional cardiovascular and neurovascular devices, minimally invasive surgical instrumentation, and novel therapeutic medical device technologies. The firm remains open to evaluating other device categories and indications on a case-by-case basis. 

From a company and management team perspective, the firm values professionalism and is willing to work with companies that do not yet have a fully built-out management team. The firm does not always require a board seat but seeks to add strategic value, particularly by facilitating corporate partnerships in Japan when appropriate. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: business, finance, health, investing, technology

Novalis Biotech is an early stage venture capital fund in life sciences. The firm’s investment ideas focus on the interaction between bio-informatics and life sciences. The firm strongly believes in applying innovative information technology to advance prevention, diagnosis, or treatment of diseases. Novalis focuses on capital light business models and platform technology. As an early stage private equity/venture capital fund, they are a dynamic and flexible player not restricting themselves to specific fields of expertise, but open to discuss any proposition in the field of life-sciences. The firm differentiates themselves by high dynamism and flexibility to rapidly evolve their portfolio companies. 
 
Novalis Biotech is interested in the diagnostics and digital health sectors. Within diagnostics, the firm is opportunistic and will consider technologies, services, and tools in development phases. Within digital health, the firm is opportunistic with interests including bioinformatics. The firm does not invest in clinical trials and will not consider traditional pharmaceuticals or medtech sectors. Indications of interest include oncology and neurology. 
 
Novalis Biotech highly values working with a top management team that is committed to the project. The firm acts as a lead investor and will require board seating. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: business, finance, health, investing, technology

A holding company manages an early-stage life sciences fund focused exclusively on private companies developing pharmaceutical products. The firm invests globally in early-stage programs, preferably with proof-of-concept validation, and supports companies from venture creation through Series A.  

Investments are made in the form of straight equity, with capital deployed over the life of the company. The firm is science-driven, may lead or co-invest, seeks board representation, and takes an active role in guiding company development and strategy. The firm does not target a fixed number of investments per year. 

In addition to the early-stage strategy, the firm also manages a late-stage vehicle focused on private pharmaceutical companies raising Series B through crossover or IPO rounds. 

Across both strategies, the firm is open to preclinical and clinical-stage therapeutic companies and is agnostic to modality and indication. The firm invests exclusively in first-in-class, breakthrough assets and does not consider repurposed drugs, diagnostics, medical devices, or incremental technologies. 

The firm prefers to invest early and support companies through major value inflection points. The firm does not impose specific requirements regarding management team composition. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: business, finance, health, investing, technology

A strategic corporate venture capital fund makes equity investments in startup companies developing innovative therapeutic products and drug-enabling platform technologies with clear potential to benefit cancer patients. Investment size is flexible depending on the opportunity. In addition to traditional equity investments, the firm may consider option-based structures and spin-outs. The firm seeks opportunities primarily in US and Europe.  

The firm focuses on early-stage opportunities, generally from research through pre-IND, targeting first-in-class or new biology-based drug discovery approaches and innovative platform technologies. The firm prioritizes assets with strategic alignment to the parent organization’s pipeline. The firm evaluates a broad range of modalities, including biologics, oncolytic viruses, and small molecules, and considers cell and gene therapy on an opportunistic basis. The primary therapeutic focus is oncology, with additional interest in immunology, allergy, musculoskeletal, and orphan indications. 

While the firm is primarily therapeutics-focused, the firm may selectively review medical device, diagnostic, or digital health technologies where there is strong strategic alignment. 

From a company and management team perspective, the firm seeks teams with strong sector expertise. With the backing of an established oncology development organization, the firm provides financial support and facilitates strategic partnerships to help advance novel research and high-potential drug candidates toward commercialization. The firm may request regional options or rights on a case-by-case basis. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: business, finance, health, investing, technology